Clinical Trials Logo

Filter by:
NCT ID: NCT05121493 Not yet recruiting - Dry Eye Syndromes Clinical Trials

Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye

Start date: May 15, 2024
Phase: N/A
Study type: Interventional

This is a single center double-masked study with up to four visits. Subjects who have been diagnosed with dry-eye syndrome at Flaum Eye Institute will be enrolled. The purpose of the study is to determine if using platelet rich plasma drops can improve clinically significant dry eye in patients and determine if there is a difference with using two different uses of the plasma tear drops: platelet rich plasma tears and plasma tears without platelets.

NCT ID: NCT05120609 Not yet recruiting - Parkinson Disease Clinical Trials

Pilot Study to Evaluate the Self-Management of Gait, Speech, and Dexterity Symptoms in Parkinson's Disease Using a Smartphone Application

Start date: December 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the impact of a smartphone application that delivers at-home therapy exercises on patients' self-management of gait, speech, and dexterity symptoms.

NCT ID: NCT05116345 Not yet recruiting - Clinical trials for Glaucoma Following Surgery

DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures

DEXTenSiVe
Start date: November 2021
Phase: Phase 4
Study type: Interventional

This is a prospective, comparative, open-label, single-center, randomized, investigator-sponsored clinical study and seeks to investigate clinical outcomes with standard of care and high dose DEXTENZA treatment compared to standard of care topical dexamethasone in patients undergoing trabeculectomy, trabeculectomy Ex-PRESS, Xen Gel stent, and Ahmed Valve surgery. Patients will be followed through 6 months. After screening a given patient for inclusion and exclusion criteria, and gaining informed consent, eyes of n=30 patients will be randomized to one of the following two groups (n=15per group) and followed from Baseline through Month 6.

NCT ID: NCT05114837 Not yet recruiting - Lymphoma Leukemia Clinical Trials

Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

Start date: September 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-center, single-arm, interventional phase I/II trial to evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg) in adults with relapsed/refractory (R/R) CD19+ B Acute Lymphocytic Leukemia (B-ALL). The study consists of two components. The dose finding component is a modified version of a Phase I trial and the extended component is a modified Phase II trial.

NCT ID: NCT05114057 Not yet recruiting - Acute Kidney Injury Clinical Trials

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI

Taking Focus 2
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

This study will follow patients admitted to the PICU with sepsis, NICU with sepsis or after abdominal surgery, or CICU who are identified as being at risk for developing acute kidney injury. The investigators will use risk-stratification, biomarker testing, and a functional assessment to predict children and neonates who will become fluid overloaded and develop severe acute kidney injury.

NCT ID: NCT05112822 Not yet recruiting - Clinical trials for Familial Adenomatous Polyposis

Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP)

Start date: March 31, 2022
Phase: Phase 1
Study type: Interventional

This is a trial that intends to evaluate the effect of treatment with the drug obeticholic acid in the treatment of the Familial Adenomatous Polyposis condition.

NCT ID: NCT05109000 Not yet recruiting - Anesthesia, Local Clinical Trials

Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline

Start date: November 2021
Phase: Phase 4
Study type: Interventional

This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject. While both normal saline and bacteriostatic saline can be administered intravenously, this study aims to investigate their effects following subcutaneous injection. While benzyl alcohol (the bacteriostatic component of bacteriostatic saline) is known to have local anesthetic properties, it also is an irritant and can cause inflammation at the injection site. Based on clinical experience investigators anticipate that a normal saline injection will cause a mild stinging sensation and no subsequent inflammation. In contrast, subcutaneous injection of bacteriostatic saline will not cause stinging but will cause a mild degree of inflammation which is manifested as mild tenderness and mild ecchymosis at the site of injection.

NCT ID: NCT05107934 Not yet recruiting - Clinical trials for Recurrent Pericarditis

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

Start date: December 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The primary purpose of this study is the evaluation of the efficacy and safety of RPH-104 treatment in patients with recurrent pericarditis. Pharmacokinetic and pharmacodynamic parameters of RPH-104 multiple doses in this patient population will be assessed as well.

NCT ID: NCT05106361 Not yet recruiting - Depression Clinical Trials

MOSAIC (MOthers' AdvocateS In the Community) for Pregnant Women and Mothers of Children Under 5 With Experience of Intimate Partner Violence

MOSAIC Plus
Start date: January 3, 2024
Phase: N/A
Study type: Interventional

The purpose of this R34 exploratory research proposal is to conduct formative work for a larger randomized controlled trial (RCT) evaluating the effectiveness of the "Mother AdvocateS In the Community (MOSAIC) Plus" intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate IPT principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms. The proposed study will enroll pregnant women who report experience of IPV in the past 6 months, and who screen positive for elevated depressive and/or PTSD symptoms. The intervention lasts 6 months after enrollment.

NCT ID: NCT05106192 Not yet recruiting - Clinical trials for Non Hodgkin Lymphoma

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

A study to compare pain differences between using MedJet needle-free drug-delivery system with standard of care treatment for cutaneous T-cell lymphomas and cutaneous B-cell lymphomas in participants.